CA2539816A1 - Antigenes pour vaccin contre la theileriose (east coast fever) - Google Patents
Antigenes pour vaccin contre la theileriose (east coast fever) Download PDFInfo
- Publication number
- CA2539816A1 CA2539816A1 CA002539816A CA2539816A CA2539816A1 CA 2539816 A1 CA2539816 A1 CA 2539816A1 CA 002539816 A CA002539816 A CA 002539816A CA 2539816 A CA2539816 A CA 2539816A CA 2539816 A1 CA2539816 A1 CA 2539816A1
- Authority
- CA
- Canada
- Prior art keywords
- polypeptide
- sequence
- animal
- parva
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000427 antigen Substances 0.000 title claims abstract 14
- 102000036639 antigens Human genes 0.000 title claims abstract 6
- 108091007433 antigens Proteins 0.000 title claims abstract 6
- 229960005486 vaccine Drugs 0.000 title claims abstract 4
- 208000001117 Theileriasis Diseases 0.000 title abstract 2
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract 35
- 241001465754 Metazoa Species 0.000 claims abstract 30
- 238000000034 method Methods 0.000 claims abstract 20
- 239000000203 mixture Substances 0.000 claims abstract 5
- 230000001717 pathogenic effect Effects 0.000 claims abstract 3
- 231100000433 cytotoxic Toxicity 0.000 claims abstract 2
- 230000001472 cytotoxic effect Effects 0.000 claims abstract 2
- 210000004698 lymphocyte Anatomy 0.000 claims abstract 2
- 229920001184 polypeptide Polymers 0.000 claims 34
- 102000004196 processed proteins & peptides Human genes 0.000 claims 34
- 102000040430 polynucleotide Human genes 0.000 claims 22
- 108091033319 polynucleotide Proteins 0.000 claims 22
- 239000002157 polynucleotide Substances 0.000 claims 22
- 241000223779 Theileria parva Species 0.000 claims 20
- 210000004027 cell Anatomy 0.000 claims 16
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 claims 8
- 208000015181 infectious disease Diseases 0.000 claims 7
- 230000000295 complement effect Effects 0.000 claims 4
- 210000004408 hybridoma Anatomy 0.000 claims 4
- 230000003053 immunization Effects 0.000 claims 4
- 230000002163 immunogen Effects 0.000 claims 4
- 230000001681 protective effect Effects 0.000 claims 3
- 102000004190 Enzymes Human genes 0.000 claims 2
- 108090000790 Enzymes Proteins 0.000 claims 2
- 208000010362 Protozoan Infections Diseases 0.000 claims 2
- 239000002671 adjuvant Substances 0.000 claims 2
- 238000003556 assay Methods 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 238000003018 immunoassay Methods 0.000 claims 2
- 210000001616 monocyte Anatomy 0.000 claims 2
- 210000005259 peripheral blood Anatomy 0.000 claims 2
- 239000011886 peripheral blood Substances 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 210000001744 T-lymphocyte Anatomy 0.000 claims 1
- 241000700605 Viruses Species 0.000 claims 1
- 230000004520 agglutination Effects 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 238000001514 detection method Methods 0.000 claims 1
- 238000005189 flocculation Methods 0.000 claims 1
- 230000016615 flocculation Effects 0.000 claims 1
- 238000003306 harvesting Methods 0.000 claims 1
- 238000011065 in-situ storage Methods 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000003550 marker Substances 0.000 claims 1
- 239000002245 particle Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 239000013612 plasmid Substances 0.000 claims 1
- 238000003127 radioimmunoassay Methods 0.000 claims 1
- 241001515965 unidentified phage Species 0.000 claims 1
- 238000001262 western blot Methods 0.000 claims 1
- 230000003834 intracellular effect Effects 0.000 abstract 2
- 108020004414 DNA Proteins 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 244000052769 pathogen Species 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/44—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from protozoa
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56905—Protozoa
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Hematology (AREA)
- Medicinal Chemistry (AREA)
- Organic Chemistry (AREA)
- Urology & Nephrology (AREA)
- Physics & Mathematics (AREA)
- Toxicology (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Analytical Chemistry (AREA)
- Biotechnology (AREA)
- Virology (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Food Science & Technology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Tropical Medicine & Parasitology (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Abstract
L'invention se rapporte à des compositions d'ADN, de protéines et de peptides p. ex. et à des procédés permettant d'identifier des antigènes intracellulaires de pathogènes qui stimulent les lymphocytes cytotoxiques animaux d'une manière spécifique des antigènes. Ces antigènes constituent des candidats de premier ordre pour la mise au point de vaccins servant à la prévention des maladies pathogènes intracellulaires telles que la theilériose (East Coast Fever).
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US50442803P | 2003-09-22 | 2003-09-22 | |
| US60/504,428 | 2003-09-22 | ||
| PCT/US2004/022605 WO2005007691A2 (fr) | 2003-07-14 | 2004-07-14 | Vaccin contre la theileriose bovine basee sur des antigenes schizont specifiques a ctl |
| USPCT/US04/022605 | 2004-07-14 | ||
| PCT/US2004/030831 WO2005030802A2 (fr) | 2003-09-22 | 2004-09-21 | Antigenes pour vaccin contre la theileriose (east coast fever) |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2539816A1 true CA2539816A1 (fr) | 2005-04-07 |
| CA2539816C CA2539816C (fr) | 2012-01-03 |
Family
ID=39930751
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2539816A Active CA2539816C (fr) | 2003-09-22 | 2004-09-21 | Antigenes pour vaccin contre la theileriose (east coast fever) |
Country Status (5)
| Country | Link |
|---|---|
| AP (1) | AP2006003594A0 (fr) |
| CA (1) | CA2539816C (fr) |
| MX (1) | MXPA06003169A (fr) |
| WO (1) | WO2005030802A2 (fr) |
| ZA (1) | ZA200603167B (fr) |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5273744A (en) * | 1989-06-14 | 1993-12-28 | International Laboratory For Research On Animal Diseases | Vaccines for the protection of animals against theileria infection |
-
2004
- 2004-09-21 WO PCT/US2004/030831 patent/WO2005030802A2/fr active Application Filing
- 2004-09-21 CA CA2539816A patent/CA2539816C/fr active Active
- 2004-09-21 MX MXPA06003169A patent/MXPA06003169A/es active IP Right Grant
- 2004-09-21 ZA ZA200603167A patent/ZA200603167B/en unknown
- 2004-09-21 AP AP2006003594A patent/AP2006003594A0/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AP2006003594A0 (en) | 2006-04-30 |
| WO2005030802A3 (fr) | 2005-09-09 |
| ZA200603167B (en) | 2008-03-26 |
| MXPA06003169A (es) | 2007-02-19 |
| CA2539816C (fr) | 2012-01-03 |
| WO2005030802A2 (fr) | 2005-04-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR20010012813A (ko) | 결핵 확인용 화합물 및 이의 사용 방법 | |
| EA022788B1 (ru) | Новые терапевтические и диагностические средства | |
| Dechamma et al. | Identification of T-helper and linear B epitope in the hypervariable region of nucleocapsid protein of PPRV and its use in the development of specific antibodies to detect viral antigen | |
| Noordhoek et al. | A new attempt to distinguish serologically the subspecies of Treponema pallidum causing syphilis and yaws | |
| WO2007005627A2 (fr) | Essais de detection d'antigenes de la tuberculose et vaccins | |
| Arévalo-Herrera et al. | Mapping and comparison of the B-cell epitopes recognized on the Plasmodium vivax circumsporozoite protein by immune Colombians and immunized Aotus monkeys | |
| CN112703197A (zh) | 嵌合免疫原性多肽 | |
| Ruan et al. | B cell and antibody responses in mice induced by a putative cell surface peptidase of Pneumocystis murina protect against experimental infection | |
| US20030170260A1 (en) | Antigenic peptide fragments of vapa protein, and uses thereof | |
| EP1141305B1 (fr) | Gene chimerique forme par les sequences d'adn codant pour les determinants antigeniques de quatre proteines de l. infantum | |
| JP2000503111A (ja) | Ｔ．ｃｒｕｚｉ感染の検出および予防のための化合物および方法 | |
| CN110257405B (zh) | 牛支原体乙醇脱氢酶基因及其编码蛋白与应用 | |
| CA2546873A1 (fr) | Polypeptides de campylobacter jejuni localises en surface | |
| US10197577B2 (en) | Serum antibody assay for determining protection from malaria, and pre-erythrocytic subunit vaccines | |
| CN107033225B (zh) | 一种小反刍兽疫病毒hn蛋白抗原表位肽及其确定、制备方法和应用 | |
| US20160216276A1 (en) | Serum antibody assay for determining protection from malaria, and pre-erythrocytic subunit vaccines | |
| KR20130088845A (ko) | 인간 사이토메갈로 바이러스 감염의 검출 방법 | |
| US6193971B1 (en) | Dictyocaulus viviparus antigen for diagnosing lungworm infestation and for vaccination | |
| CA2539816A1 (fr) | Antigenes pour vaccin contre la theileriose (east coast fever) | |
| AU777145B2 (en) | Antigenic protein LPPQ of Mycoplasma mycoidessubsp.(mycoides)SC., its preparation and use | |
| CN113845577A (zh) | SARS-CoV-2特异性多肽及其应用 | |
| US6783759B2 (en) | Compositions and methods for modulating variola virus | |
| US6521229B1 (en) | 41 kDa Cryptosporidium parvum oocyst wall protein | |
| US9562080B2 (en) | Lyme disease vaccine, genetic construct, recombinant protein, method for designing genetic construct, method for producing vaccine, method for producing recombinant proteins, use of recombinant proteins in the production of lyme disease vaccine | |
| CN101052412B (zh) | 阿米巴病亚单位疫苗 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |